CDRT15P9

Across TCGA pan-cancer cohorts, CDRT15P9 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CDRT15P9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CDRT15P9 RNA is repressed in tumor relative to normal tissue. In most cancer types CDRT15P9 is over-expressed in tumor, although a few such as KIRC and BRCA show the opposite, repressed pattern.

KIRC, BRCA, and LIHC are the cancer types where CDRT15P9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDRT15P9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−0.272	.007	6	view →
BRCA	Female	II,III,IV	−0.307	.007	4	view →
LIHC	All	All	+0.399	<.001	3	view →
STAD	All	IV	−0.250	.005	3	view →
ESCA	All	All	−0.253	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CDRT15P9–KIRC

Open the KIRC breakdown →